This article is more than 5 years old. Information may no longer be current.

FDA gives greenlight for phase 2 study of travoprost with iDose delivery system

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA will allow Glaukos to initiate a U.S. investigational new drug phase 2 study of a travoprost intraocular implant with the iDose delivery system in patients with glaucoma, according to a press release.

“We are very pleased that the FDA is allowing this trial to begin several months in advance of our original target date,” Thomas Burns, president and CEO of Glaukos, said in the release.

The phase 2 study follows the recent investigational new drug submission to the FDA, in which Glaukos proposed conducting a randomized trial to assess the safety and preliminary efficacy of two models of the iDose delivery system with different travoprost elution rates in comparison to timolol maleate ophthalmic solution 0.5%, the release said.